PDUFA date

The deadline by which the FDA must complete its review of a new drug application and issue a decision.

A PDUFA date is a highly anticipated deadline by which the U.S. Food and Drug Administration (FDA) must complete its review of a new drug or biologic application and issue its regulatory decision. Established under the Prescription Drug User Fee Act, these dates provide a transparent timeline for pharmaceutical companies and the public, indicating when a treatment is likely to be approved or rejected. The FDA calculates the PDUFA date based on when it formally accepts a company's application. Standard reviews typically target a 10-month timeline, while applications granted priority review are fast-tracked for a 6-month target. If the FDA requests major additional data during the review process, the deadline can be extended, usually by three months. For healthcare and biotechnology investors, the PDUFA date represents a critical binary event. Leading up to this date, a stock's volatility often spikes as traders speculate on the outcome. A positive decision can send a micro-cap or mid-cap biotech stock up by hundreds of percent, while a rejection—often delivered via a Complete Response Letter (CRL)—can wipe out the majority of a company's market value in a single session. Investors track these dates closely to manage risk, adjust position sizes, or utilize options strategies to hedge against extreme price swings.

A clinical-stage biotech company submits a New Drug Application (NDA) which is accepted by the FDA on May 15, 2026. Because the drug targets an unmet medical need, it receives a Priority Review designation. The FDA sets a 6-month review clock, establishing a PDUFA action date of November 15, 2026, by which it must approve the drug or issue a Complete Response Letter.